Frequency of metabolic syndrome in obsessive compulsive disorder patients on antidepressant monotherapy vs antidepressant plus atypical antipsychotic combination therapy: A naturalistic, descriptive pilot study;Antidepresanla birlikte atipik antipsikotik ekleme tedavisi kullanan ve kullanmayan obsesif kompulsif bozukluk hastalarinda metabolik sendrom sikliǧi: Naturalistik, tanimlayici bir ön çalişma

Klinik Psikofarmakoloji Bulteni

Volumn 20, Issue 4, 2010, Pages 307-313

  Savaş, Esen ^a   Özovaci, Arzu ^a   Kokaçya, Mehmet Hanifi ^b   Altindaǧ, Abdurrahman ^a   Virit, Osman ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Devlet Hastanesi   (Turkey)

Author keywords

Antidepressants; Atypical antipsychotics; Dyslipidemia; Medicines; Metabolic syndrome; Obesity; Obsessive compulsive disorder; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BLOOD PRESSURE; BODY HEIGHT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DEMENTIA; DIET RESTRICTION; DISEASE ASSOCIATION; EDUCATION; EMPLOYMENT STATUS; EPILEPSY; FISHER EXACT TEST; GENDER; GLUCOSE BLOOD LEVEL; HEAD INJURY; HUMAN; MARRIAGE; MENTAL DEFICIENCY; METABOLIC DISORDER; NATURALISTIC INQUIRY; NEUROLOGIC DISEASE; OBSESSIVE COMPULSIVE DISORDER; OUTPATIENT; PILOT STUDY; PREGNANCY; SMOKING; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUBSTANCE ABUSE; VENOUS BLOOD; WAIST CIRCUMFERENCE;

EID: 79251495752     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.1080/10177833.2010.11790677     Document Type: Article

References (42)

1. Choi YJ. Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review.J Am Acad Nurse Pract. 2009;21:207-213.
2. Işik E. Güncel Şizofreni. (1. baski). Ankara, Asimetrik Paralel, 2006:37-46.
3. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease. Diabetologia. 1994;37:948-952.
4. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med.1989;149:1514-1520.
5. DeFronzo RA, Ferannini E. Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertansion, Dyslipidemia and Atherosclerotic Cardiovascular Disease. Diabetes Care. 1991;14:173-194.
6. Toalson P, Ahmed S, Hardy T, Kabinoff G. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry. 2004;6:152-158.
7. Sung-Hwan Kim, Kiwon Kim, Mi Hyang Kwak, Hak Jin Kim, Hong-Sup Kim, aKi Hoon Han. The Contribution of Abdominal Obesity and Dyslipidemia to Metabolic Syndrome in Psychiatric Patients. Korean J Intern Med. 2010; 25:168-173.
8. Basu R, Brar JS, Chengappa KN, John V, Parepally H, Gershon S et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder- bipolar subtype. Bipolar Disord. 2004;6:314-318. (Pubitemid 39077092)
9. Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65:1365-1371.
10. Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, Savas E et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord. 2007;98:247-252. (Pubitemid 46151723)
11. Kaya MC, Virit O, Altindaǧ A, Selek S, Bülbül F, Bulut M, Savaş HA. Şizofrenide Metabolik Sendrom Sikliǧi, Metabolik Sendromun Özellikleri ve Kullanilan Antipsikotiklerle İlişkisi NöroPsikiyatri Arşivi 2009; 46:13-18.
12. Yumru M, Savaş E, Gergerlioǧlu HS, Başarali K, Kalenderoǧlu A, Savaş HA, Büyükbaş S İkiuçlu Bozuklukta Metabolik Sendrom, Serum Leptin Düzeyleri ve Tedavi İlişkisi Klinik Psikofarmakoloji Bülteni - Bulletin of Clinical Psychopharmacology 2008; 18:79-83.
13. Vural M: Şizofreni ve bipolar affektif bozukluk hastalarinda antipsikotik ilaç kullanimi ile metabolik sendrom ve diǧer metabolik süreçlerin ilişkisinin incelenmesi. Uzmanlik Tezi, Haydarpaşa Numune Eǧitim ve Araştirma Hastanesi, Psikiyatri Kliniǧi. İstanbul 2007 (yayinlanmamiş), s.1-43.
14. National Cholesterol Education Program Coordinating Committee, Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation 2002; 106: 3143-3421.
15. Maina G, Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2008;18:364-372.
16. Arias Horcajadas F, Soto JA, García-Cantalapiedra MJ, Rodríguez Calvin JL, Morales J, Salgado M. Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors. Actas Esp Psiquiatr. 2006;34:147-152.
17. Yoshimura R, Kaneko S, Shinkai K, Nakamura J. Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. Psychiatry Clin Neurosci. 2006;60:389-393.
18. Savas HA, Yumru M, Ozen ME. Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study. Clin Drug Investig. 2008;28:439-442. (Pubitemid 351821481)
19. Vulink NC, Denys D, Fluitman SB, Meinardi JC, Westenberg HG. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry. 2009;70:1001-1008.
20. Iglesias Garcia C, Santamarina Montila S, Alonso Villa MJ. Ziprasidone as coadjuvant treatment in resistant obsessive-compulsive disorder treatment. Actas Esp Psiquiatr. 2006;34:277-279. (Pubitemid 44196653)
21. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11:622-632. (Pubitemid 43989810)
22. D'Amico G, Cedro C, Muscatello MR, Pandolfo G, Di Rosa AE, Zoccali R et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:619-263. (Pubitemid 36645062)
23. Amerikan Psikiyatri Birligi: Ruhsal Bozukluklarin Tanisal ve Sayimsal Elkitabi, Dördüncü Baski, Yeniden Gözden Geçirilmis Tam Metin (DSM-IV-TR), Washington DC, Amerikan Psikiyatri Birliǧi, 2000, Köroǧlu E (çeviri ed.), Ankara, Hekimler Yayin Birliǧi, 2007;660-671.
24. http://www.tuik.gov.tr/ZipGetir.do?id=4044. Erişim tarihi17.06.2010
25. Onat A, Özhan H, Esen AM Albayrak S, Karabulut A, Can G, Hergenç G. Prospective epidemiologic evidence of a "protective" effect of smoking on metabolic syndrome and diabetes among Turkish women-without associated overall health benefit. J Atherosclerosis 2007; 193:380-8.
26. Onat A, Hergenç G, Küçükdurmaz Z, Uǧur M, Kaya Z, Can G, Yüksel H. Moderate and heavy alcohol consumption among Turks: Long-term impact on mortality and cardiometabolic risk. Türk Kardiyol Dern Arş 2009; 37: 83-90.
27. Çelikel F, Bingöl Y, Yildirim D, Tel H, Erkorkmaz Ü. Obsesif kompulsif bozukluk hastalarinda yeme tutumu. Nöropsikiyatri Arşivi 2009; 46: 86-90.
28. Skilton MR, Moulin P, Terra JL, Bonnet F. Associations between anxiety, depression, and the metabolic syndrome. Biol Psychiatry. 2007;62:1251-1257. (Pubitemid 350060887)
29. Van Reedt Dortland AK, Giltay EJ, van Veen T, Zitman FG, Penninx BW. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta psychiatr scand. 2010;122:30-39.
30. Pulular A: Edirne ili merkezindeki lise öǧrencilerinde obsesif kompulsif bozukluǧun epidemiyolojisi. Uzmanlik tezi, Trakya Üniv. Tip Fakültesi Psikiyatri Anabilim Dali. Edirne 2009 (yayinlanmamiş) s.34.
31. Heyman I, Fombonne E, Simmons H, Ford T, Meltzer H, Goodman R. Prevalence of obsessive-compulsive disorder in the British nationwide survey of child mental health. Int Rev Psychiatr. 2003;15:178-84.
32. Geller DA, Biederman J, Jones J, Shapiro S, Schwartz S, Park KS. Obsessive compulsive-disorder in children and adolescents: A Review. Harv Rev Psychiatry.1998;5:260-73.
33. Millet B, Kochman F, Gallarda T, Krebs MO, Demonfaucon F, Barrot I et al. Phenomenological and comorbid features associated in obsessive-compulsive disorder: Influence of age of onset. J Affect Disord. 2004;79:241-246.
34. Torres AR, Prince MJ, Bebbington PE, Bhugra D, Brugha TS, Farrell M et al. Obsessive-compulsive disorder: Prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000. Am J Psychiatry. 2006;163:1978-1985.
35. Jacob R, Chowdhury AN. Metabolic comorbidity in schizophrenia. Indian J Med Sci. 2008;62:23-31.
36. Cerit C, Özten E, Yildiz M. Şizofreni hastalarinda metabolik sendrom sikliǧi ve ilişkili etmenler. Türk Psikiyatri Dergisi. 2008;19:124-132.
37. Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003;64:575-579.
38. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;24:7-14.
39. Altinbaş K, Kurt E, Oral ET. İkinci kuşak antipsikotiklerin endokrin yan etkileri: istisna mi, kural mi? Anadolu Psikiyatri Dergisi. 2005;6:259-266.
40. Baptista T, Kin NM, Beaulieu S, Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: Mechanisms, management and research perspectives. Pharmacopsychiatry. 2002;35:205-219.
41. Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004 ;65:1040-1048.
42. Onat A, Sansoy V. Halkimizda koroner hastaliǧin baş suçlusu metabolik sendrom: Sikliǧi, unsurlari, koroner risk ile ilişkisi ve yüksek risk kriterleri. Türk Kardiyol Dern Arş. 2002;30:8-15.